Tazidime and Osteoarthritis - a phase IV clinical study of FDA data

Summary:

Osteoarthritis is reported as a side effect among people who take Tazidime (ceftazidime), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Tylenol, and have Enterococcal infection.

The phase IV clinical study analyzes which people have Osteoarthritis when taking Tazidime. It is created by eHealthMe based on reports of 10,389 people who have side effects when taking Tazidime from the FDA, and is updated regularly.

What is Tazidime?

Tazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,409 Tazidime users. Check the latest studies of Tazidime.

What is Osteoarthritis?

Osteoarthritis (a joint disease caused by cartilage loss in a joint) is found to be associated with 1,880 drugs and 2,648 conditions by eHealthMe. Check the latest studies of Osteoarthritis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

10,389 people reported to have side effects when taking Tazidime.
Among them, 84 people (0.81%) have Osteoarthritis.

Among these 84 people:

How long have people been on Tazidime when they have Osteoarthritis? *

What is the gender of people who have Osteoarthritis when taking Tazidime? *

female: 85.71 %
male: 14.29 %

What is the age of people who have Osteoarthritis when taking Tazidime? *

What are other drugs people take besides Tazidime? *

What are other side effects people have besides Osteoarthritis? *

Nausea (feeling of having an urge to vomit): 75 people, 89.29%
Weakness: 70 people, 83.33%
Depression: 69 people, 82.14%
Neuropathy Peripheral (surface nerve damage): 68 people, 80.95%
Nausea And Vomiting: 66 people, 78.57%
Abdominal Pain: 64 people, 76.19%
Pneumonia: 63 people, 75.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 63 people, 75.00%
High Blood Pressure: 63 people, 75.00%
Herpes Zoster: 61 people, 72.62%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 51 people, 60.71%
Enterococcal Infection: 51 people, 60.71%
Generalised Oedema (swelling all over the body): 49 people, 58.33%
Multiple Myeloma (cancer of the plasma cells): 8 people, 9.52%
High Blood Pressure: 6 people, 7.14%
Metastases To Bone (cancer spreads to bone): 5 people, 5.95%
Febrile Neutropenia (fever with reduced white blood cells): 5 people, 5.95%
Breast Cancer: 4 people, 4.76%
Osteomyelitis (infection of bone): 4 people, 4.76%
Bone Cancer Metastatic: 4 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Tazidime and have Osteoarthritis?

- Check whether Osteoarthritis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tazidime:

Tazidime (10,409 reports)

Osteoarthritis treatments and more:

Osteoarthritis (95,655 reports)

Browse all side effects of Tazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteoarthritis:

Osteoarthritis (1,880 drugs)

Browse all the conditions that are associated with Osteoarthritis:

Osteoarthritis (2,648 conditions)

Related publications that referenced our studies

Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .
Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime (the active ingredients of Tazidime) and Tazidime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.